Prevention of Hyperglycemic Signal Pathways in Metabolic Syndrome Carotid Artery of Rats

Hiromi Kawai, Fengfeng Tian, Tomoko Kurata, Kentaro Deguchi, Toru Yamashita, Yoshio Omote, Syoichiro Kono, Koji Abe

Research output: Contribution to journalArticle

Abstract

Obesity is the major risk factor for metabolic syndrome and atherosclerotic cardiocerebrovascular diseases and induces insulin resistance characterized by a dysfunction of insulin to activate insulin receptor /insulin receptor substrate 1(IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt pathway. Zucker fatty rats (8 weeks) were treated with vehicle (0. 5 % methyl cellulose in physiological saline, p. o.), amlodipine (3 mg/kg/day, p. o.), atorvastatin (10 mg/kg/day, p. o.), or the combination of amlodipine plus atorvastatin (3 + 10 mg/kg/day, p. o.) for 28 days, and anti-insulin-like growth factor 1 (IGF-1)/IRS-1/PI3K/Akt pathways were evaluated. Our present immunohistochemical study first demonstrated that a combination of amlodipine plus atorvastatin treatment prevented an arteriosclerotic process compared to the single treatment with amlodipine or atorvastatin with strong recoveries of pTyr IRS-1, pPI3K, and pAkt expressions and with remarkable restraints of IGF-1 and pSer IRS-1. As a result, combination therapy with amlodipine plus atorvastatin showed a strong synergistic effect to prevent atherosclerotic processes. The present study newly suggests a synergistic benefit of combination therapy with amlodipine plus atorvastatin for strong prevention of atherosclerotic processes, which could reduce the clinical risk of cerebrovascular events for obesity patients.

Original languageEnglish
Pages (from-to)466-472
Number of pages7
JournalTranslational Stroke Research
Volume3
Issue number4
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Insulin Receptor Substrate Proteins
Carotid Arteries
Signal Transduction
1-Phosphatidylinositol 4-Kinase
Somatomedins
Obesity
Zucker Rats
Amlodipine
Methylcellulose
Insulin Receptor
Therapeutics
Insulin Resistance
atorvastatin drug combination amlodipine
Insulin

Keywords

  • Amlodipine
  • Atorvastatin
  • Common carotid artery
  • Zucker fatty rat

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Prevention of Hyperglycemic Signal Pathways in Metabolic Syndrome Carotid Artery of Rats. / Kawai, Hiromi; Tian, Fengfeng; Kurata, Tomoko; Deguchi, Kentaro; Yamashita, Toru; Omote, Yoshio; Kono, Syoichiro; Abe, Koji.

In: Translational Stroke Research, Vol. 3, No. 4, 12.2012, p. 466-472.

Research output: Contribution to journalArticle

Kawai, Hiromi ; Tian, Fengfeng ; Kurata, Tomoko ; Deguchi, Kentaro ; Yamashita, Toru ; Omote, Yoshio ; Kono, Syoichiro ; Abe, Koji. / Prevention of Hyperglycemic Signal Pathways in Metabolic Syndrome Carotid Artery of Rats. In: Translational Stroke Research. 2012 ; Vol. 3, No. 4. pp. 466-472.
@article{b4108fceab65422cb0ba802fa9cf855f,
title = "Prevention of Hyperglycemic Signal Pathways in Metabolic Syndrome Carotid Artery of Rats",
abstract = "Obesity is the major risk factor for metabolic syndrome and atherosclerotic cardiocerebrovascular diseases and induces insulin resistance characterized by a dysfunction of insulin to activate insulin receptor /insulin receptor substrate 1(IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt pathway. Zucker fatty rats (8 weeks) were treated with vehicle (0. 5 {\%} methyl cellulose in physiological saline, p. o.), amlodipine (3 mg/kg/day, p. o.), atorvastatin (10 mg/kg/day, p. o.), or the combination of amlodipine plus atorvastatin (3 + 10 mg/kg/day, p. o.) for 28 days, and anti-insulin-like growth factor 1 (IGF-1)/IRS-1/PI3K/Akt pathways were evaluated. Our present immunohistochemical study first demonstrated that a combination of amlodipine plus atorvastatin treatment prevented an arteriosclerotic process compared to the single treatment with amlodipine or atorvastatin with strong recoveries of pTyr IRS-1, pPI3K, and pAkt expressions and with remarkable restraints of IGF-1 and pSer IRS-1. As a result, combination therapy with amlodipine plus atorvastatin showed a strong synergistic effect to prevent atherosclerotic processes. The present study newly suggests a synergistic benefit of combination therapy with amlodipine plus atorvastatin for strong prevention of atherosclerotic processes, which could reduce the clinical risk of cerebrovascular events for obesity patients.",
keywords = "Amlodipine, Atorvastatin, Common carotid artery, Zucker fatty rat",
author = "Hiromi Kawai and Fengfeng Tian and Tomoko Kurata and Kentaro Deguchi and Toru Yamashita and Yoshio Omote and Syoichiro Kono and Koji Abe",
year = "2012",
month = "12",
doi = "10.1007/s12975-012-0205-6",
language = "English",
volume = "3",
pages = "466--472",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "4",

}

TY - JOUR

T1 - Prevention of Hyperglycemic Signal Pathways in Metabolic Syndrome Carotid Artery of Rats

AU - Kawai, Hiromi

AU - Tian, Fengfeng

AU - Kurata, Tomoko

AU - Deguchi, Kentaro

AU - Yamashita, Toru

AU - Omote, Yoshio

AU - Kono, Syoichiro

AU - Abe, Koji

PY - 2012/12

Y1 - 2012/12

N2 - Obesity is the major risk factor for metabolic syndrome and atherosclerotic cardiocerebrovascular diseases and induces insulin resistance characterized by a dysfunction of insulin to activate insulin receptor /insulin receptor substrate 1(IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt pathway. Zucker fatty rats (8 weeks) were treated with vehicle (0. 5 % methyl cellulose in physiological saline, p. o.), amlodipine (3 mg/kg/day, p. o.), atorvastatin (10 mg/kg/day, p. o.), or the combination of amlodipine plus atorvastatin (3 + 10 mg/kg/day, p. o.) for 28 days, and anti-insulin-like growth factor 1 (IGF-1)/IRS-1/PI3K/Akt pathways were evaluated. Our present immunohistochemical study first demonstrated that a combination of amlodipine plus atorvastatin treatment prevented an arteriosclerotic process compared to the single treatment with amlodipine or atorvastatin with strong recoveries of pTyr IRS-1, pPI3K, and pAkt expressions and with remarkable restraints of IGF-1 and pSer IRS-1. As a result, combination therapy with amlodipine plus atorvastatin showed a strong synergistic effect to prevent atherosclerotic processes. The present study newly suggests a synergistic benefit of combination therapy with amlodipine plus atorvastatin for strong prevention of atherosclerotic processes, which could reduce the clinical risk of cerebrovascular events for obesity patients.

AB - Obesity is the major risk factor for metabolic syndrome and atherosclerotic cardiocerebrovascular diseases and induces insulin resistance characterized by a dysfunction of insulin to activate insulin receptor /insulin receptor substrate 1(IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt pathway. Zucker fatty rats (8 weeks) were treated with vehicle (0. 5 % methyl cellulose in physiological saline, p. o.), amlodipine (3 mg/kg/day, p. o.), atorvastatin (10 mg/kg/day, p. o.), or the combination of amlodipine plus atorvastatin (3 + 10 mg/kg/day, p. o.) for 28 days, and anti-insulin-like growth factor 1 (IGF-1)/IRS-1/PI3K/Akt pathways were evaluated. Our present immunohistochemical study first demonstrated that a combination of amlodipine plus atorvastatin treatment prevented an arteriosclerotic process compared to the single treatment with amlodipine or atorvastatin with strong recoveries of pTyr IRS-1, pPI3K, and pAkt expressions and with remarkable restraints of IGF-1 and pSer IRS-1. As a result, combination therapy with amlodipine plus atorvastatin showed a strong synergistic effect to prevent atherosclerotic processes. The present study newly suggests a synergistic benefit of combination therapy with amlodipine plus atorvastatin for strong prevention of atherosclerotic processes, which could reduce the clinical risk of cerebrovascular events for obesity patients.

KW - Amlodipine

KW - Atorvastatin

KW - Common carotid artery

KW - Zucker fatty rat

UR - http://www.scopus.com/inward/record.url?scp=84869867598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869867598&partnerID=8YFLogxK

U2 - 10.1007/s12975-012-0205-6

DO - 10.1007/s12975-012-0205-6

M3 - Article

VL - 3

SP - 466

EP - 472

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 4

ER -